The Corporate Luncheon Workshops are independent from the ISLH educational content. Please review the available workshops below and pre-register for any workshops that you wish to attend. There is no cost to attend these workshops. Corporate luncheon workshops are limited to meeting attendees. Details are subject to change.
LUNCHEON WORKSHOP PRE-REGISTRATION WILL OPEN APRIL 8.If you have already registered for the conference
Chair: Gabriella Lakos, MD, PhD (Medical Affairs, Abbott Diagnostics Division)
The Analytical Performance of the Alinity h-series System
Description: During this symposium, the performance of the Alinity h-series system as compared to other high-throughput, on-market systems will be reviewed. In addition, the performance of the Alinity h-series WBC differential will be discussed versus manual WBC differential results on a cohort of normal and pathological samples.
Alinity h-series is not commercially available in all countries, including the US.
Advanced Applications of Optical RBC Technology in Diagnosis and Patient Management
Description: Advanced hematology systems can perform analysis of red blood cells using entirely optical technology, allowing for the introduction of additional parameters. In this presentation, the advantages of optical technology in characterizing RBCs will be discussed. The application of these parameters and their impact on diagnosis and patient management will be reviewed.
For the past two decades, CellaVision has helped hematology labs all over the world innovate the process of performing blood cell differentials. In our Luncheon workshop a panel of experts will provide interesting perspectives and commentary on the utility and value of Digital Cell Morphology.Introduction
Brief introduction of the CellaVision® DC-1. An analyzer custom-designed for implementation in small low-volume hematology laboratories.
Speaker: Ron Hagner, VP commercial Development, CellaVision
Experiences and thoughts on using CellaVision DC-1 to improve the performance of a geographically dispersed organization.
Speaker: Dr. Etienne Mahe, Calgary Lab Services, Canada
The results of a survey evaluating the user experience of a group of Medical technologists asked to perform blood cell differentials using CellaVision DC-1.
Speaker: Dr. Brian Berry, Vancouver Island Health Authority, Canada
This session will discuss abnormalities in platelet morphology encountered during peripheral blood smear review. The session will include the clinical and laboratory relevance of large platelets, hypogranular platelets and platelet clumps; and strategies for reporting these findings.
Speaker: Steven Marionneaux, Scientific and Medical Affairs Advisor, CellaVision
Speaker: Hina Chaudhry, HBSc, MLT, Research Program Manager – CELTIC Connect, St Michael's Hospital, Toronto
One of the limitations with standard clotting factor concentrates given prophylactically is that they have short half‐lives. Factor VIII is around 12 hours and factor IX around 24 hours. To maintain therapeutic levels, intravenous infusion of these concentrates is required three or more times a week for hemophilia A and twice a week for hemophilia B. As technology has advanced, more products have been developed that feature modifications of the clotting factor protein molecule intended to achieve improved therapeutic properties. Extended half‐ life products have been bio‐engineered to stay longer in circulation and reduce the number of infusions required to maintain good levels of the clotting factors. These new extended life products have half‐lives 2 to 5 times longer than standard factor VII and IX so patient therapies are only required less frequently.
Implementation of these new bio-engineered products into clinical practice requires the ability for the lab to know what products are in use, the ability to accurately measure factor levels and monitor for inhibitory antibodies. Many laboratories in the utilize standard APTT based one-stage clotting assays to measure factor levels which may not be appropriate for these new bio-engineered agents. This presentation will cover Hemophilia A and B (VIII/IX), the new extended life recombinant products currently available across Canada, testing for the new products, methods currently available in Canada and experiences and data for assays in use.
Dr. Mathew Estey (DynaLIFE Medical Labs, Edmonton, Canada) will explain why the laboratory has chosen capillary electrophoresis as the first-line technique for the detection of haemoglobinopathies and thalassaemias. Based on several years of experience and routine use, he will demonstrate how this technology, thanks to better analytical performance and ergonomics, has improved the diagnosis of these diseases and has brought increased medical value for patients.
Dr. Barbara De La Salle (UK NEQAS Haematology, Watford, UK) will discuss the performance assessment of haemoglobin testing by Sebia capillary electrophoresis in external quality assessment and proficiency testing. She will also review recent developments in Hb A2 standardization and the importance of accurate Hb A2 measurement in Beta-thalassaemia carrier diagnosis.
Dr. Olga Pozdnyakova, MD, PhD, Associate Professor of Pathology, Harvard Medical School, Division of Hematopathology, Brigham & Women's Hospital, Boston, MA
Dr. Emily Mason, MD, PhD, Assistant Professor of Pathology, Microbiology, and Immunology, Division of Hematopathology, Vanderbilt University Medical Center, Nashville, TN